» Articles » PMID: 23776481

A Novel Glucagon-related Peptide (GCRP) and Its Receptor GCRPR Account for Coevolution of Their Family Members in Vertebrates

Overview
Journal PLoS One
Date 2013 Jun 19
PMID 23776481
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The glucagon (GCG) peptide family consists of GCG, glucagon-like peptide 1 (GLP1), and GLP2, which are derived from a common GCG precursor, and the glucose-dependent insulinotropic polypeptide (GIP). These peptides interact with cognate receptors, GCGR, GLP1R, GLP2R, and GIPR, which belong to the secretin-like G protein-coupled receptor (GPCR) family. We used bioinformatics to identify genes encoding a novel GCG-related peptide (GCRP) and its cognate receptor, GCRPR. The GCRP and GCRPR genes were found in representative tetrapod taxa such as anole lizard, chicken, and Xenopus, and in teleosts including medaka, fugu, tetraodon, and stickleback. However, they were not present in mammals and zebrafish. Phylogenetic and genome synteny analyses showed that GCRP emerged through two rounds of whole genome duplication (2R) during early vertebrate evolution. GCRPR appears to have arisen by local tandem gene duplications from a common ancestor of GCRPR, GCGR, and GLP2R after 2R. Biochemical ligand-receptor interaction analyses revealed that GCRP had the highest affinity for GCRPR in comparison to other GCGR family members. Stimulation of chicken, Xenopus, and medaka GCRPRs activated Gαs-mediated signaling. In contrast to chicken and Xenopus GCRPRs, medaka GCRPR also induced Gαq/11-mediated signaling. Chimeric peptides and receptors showed that the K(16)M(17)K(18) and G(16)Q(17)A(18) motifs in GCRP and GLP1, respectively, may at least in part contribute to specific recognition of their cognate receptors through interaction with the receptor core domain. In conclusion, we present novel data demonstrating that GCRP and GCRPR evolved through gene/genome duplications followed by specific modifications that conferred selective recognition to this ligand-receptor pair.

Citing Articles

Evolution of GCGR family ligand-receptor extensive cross-interaction systems suggests a therapeutic direction for hyperglycemia in mammals.

Liu J, Wang X, Zhang W, Liao G, Shao Z, Brosius J Acta Biochim Biophys Sin (Shanghai). 2023; 55(12):1855-1863.

PMID: 37969012 PMC: 10753361. DOI: 10.3724/abbs.2023133.


Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals.

Irwin D Front Endocrinol (Lausanne). 2021; 12:700066.

PMID: 34322093 PMC: 8312260. DOI: 10.3389/fendo.2021.700066.


Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.

Holscher C Br J Pharmacol. 2021; 179(4):695-714.

PMID: 33900631 PMC: 8820183. DOI: 10.1111/bph.15508.


Elucidating the Relationship Between Diabetes Mellitus and Parkinson's Disease Using F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2.

Kong Y, Zhou H, Feng H, Zhuang J, Wen T, Zhang C Front Neurosci. 2020; 14:682.

PMID: 32760240 PMC: 7372188. DOI: 10.3389/fnins.2020.00682.


Exploring the molecular structures that confer ligand selectivity for galanin type II and III receptors.

Lee Y, Reyes-Alcaraz A, Yun S, Lee C, Hwang J, Seong J PLoS One. 2020; 15(3):e0230872.

PMID: 32231393 PMC: 7108740. DOI: 10.1371/journal.pone.0230872.


References
1.
Lee Y, Tsunekawa K, Moon M, Um H, Hwang J, Osugi T . Molecular evolution of multiple forms of kisspeptins and GPR54 receptors in vertebrates. Endocrinology. 2009; 150(6):2837-46. DOI: 10.1210/en.2008-1679. View

2.
Irwin D, Prentice K . Incretin hormones and the expanding families of glucagon-like sequences and their receptors. Diabetes Obes Metab. 2011; 13 Suppl 1:69-81. DOI: 10.1111/j.1463-1326.2011.01444.x. View

3.
Li J, Choe H, Wang A, Maiti K, Wang C, Salam A . Extracellular loop 3 (EL3) and EL3-proximal transmembrane helix 7 of the mammalian type I and type II gonadotropin-releasing hormone (GnRH) receptors determine differential ligand selectivity to GnRH-I and GnRH-II. Mol Pharmacol. 2005; 67(4):1099-110. DOI: 10.1124/mol.104.004887. View

4.
Nauck M, Heimesaat M, Behle K, Holst J, Nauck M, Ritzel R . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87(3):1239-46. DOI: 10.1210/jcem.87.3.8355. View

5.
Zander M, Madsbad S, Madsen J, Holst J . Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359(9309):824-30. DOI: 10.1016/S0140-6736(02)07952-7. View